

Jiejie Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1164160/publications.pdf>

Version: 2024-02-01

155
papers

3,843
citations

172457

29
h-index

189892

50
g-index

157
all docs

157
docs citations

157
times ranked

5900
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut, 2019, 68, 1764-1773.	12.1	219
2	Tumor-infiltrating Neutrophils is Prognostic and Predictive for Postoperative Adjuvant Chemotherapy Benefit in Patients With Gastric Cancer. Annals of Surgery, 2018, 267, 311-318.	4.2	176
3	Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2018, 24, 3069-3078.	7.0	124
4	Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. European Urology, 2019, 75, 752-763.	1.9	123
5	Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer, 2015, 18, 740-750.	5.3	118
6	Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. Carcinogenesis, 2015, 36, 1136-1143.	2.8	107
7	Prognostic Value of Diametrically Polarized Tumor-Associated Macrophages in Renal Cell Carcinoma. Annals of Surgical Oncology, 2014, 21, 3142-3150.	1.5	98
8	EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nature Communications, 2015, 6, 8494.	12.8	95
9	Tumor infiltrating CD19 ⁺ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Oncoimmunology, 2018, 7, 1-9.	4.6	93
10	Intratumoral CXCL13 ⁺ CD8 ⁺ T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. , 2021, 9, e001823.		87
11	Hepatitis B Virus Large Surface Antigen Promotes Liver Carcinogenesis by Activating the Src/PI3K/Akt Pathway. Cancer Research, 2011, 71, 7547-7557.	0.9	78
12	Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU International, 2016, 117, 351-362.	2.5	76
13	Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Scientific Reports, 2016, 6, 21319.	3.3	73
14	Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. Cancer Immunology, Immunotherapy, 2020, 69, 1565-1576.	4.2	72
15	Hepatitis B Virus X Protein Confers Resistance of Hepatoma Cells to Anoikis by Up-regulating and Activating p21-Activated Kinase 1. Gastroenterology, 2012, 143, 199-212.e4.	1.3	70
16	Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. Oncoimmunology, 2018, 7, e1474317.	4.6	61
17	Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer. Cancer Research, 2020, 80, 1707-1719.	0.9	61
18	Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. Oncoimmunology, 2017, 6, e1293211.	4.6	57

#	ARTICLE	IF	CITATIONS
19	Discovery of Specific Metastasis-Related N-Glycan Alterations in Epithelial Ovarian Cancer Based on Quantitative Glycomics. <i>PLoS ONE</i> , 2014, 9, e87978.	2.5	45
20	High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma. <i>Scientific Reports</i> , 2015, 5, 16954.	3.3	43
21	CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 261-269.	4.2	43
22	Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. <i>Journal of Urology</i> , 2016, 196, 1363-1370.	0.4	42
23	Tumor infiltrating mast cells determine oncogenic HIF-2 α -conferred immune evasion in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 731-741.	4.2	39
24	CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 45-56.	4.2	39
25	Tumor-infiltrating $\gamma\delta$ T cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. <i>Oncotmunology</i> , 2017, 6, e1353858.	4.6	38
26	Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma. <i>Experimental Hematology and Oncology</i> , 2021, 10, 36.	5.0	36
27	CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1855-1867.	4.2	35
28	Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients. , 2020, 8, e000447.		35
29	The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients. <i>BMC Cancer</i> , 2015, 15, 766.	2.6	34
30	Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 2067-2080.	4.2	34
31	Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103+CD8+ T cells conferring favourable prognosis. <i>British Journal of Cancer</i> , 2020, 122, 1525-1534.	6.4	34
32	Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. <i>Nature Communications</i> , 2021, 12, 3080.	12.8	34
33	Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 1435-1442.	1.5	33
34	CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 51525-51534.	1.8	32
35	High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 340.e1-340.e8.	1.6	31
36	Clinical significance of tumor-derived IL-1 β and IL-18 in localized renal cell carcinoma: Associations with recurrence and survival1Contributed equally to this work.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 68.e9-68.e16.	1.6	31

#	ARTICLE	IF	CITATIONS
37	Identification of Î ² -1,4-galactosyltransferase I as a target gene of HBx-induced cell cycle progression of hepatoma cell. Journal of Hepatology, 2008, 49, 1029-1037.	3.7	30
38	P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma. Cancer Science, 2015, 106, 1224-1231.	3.9	30
39	Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 349-355.	1.6	30
40	Stromal LAG-3 ⁺ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture. , 2020, 8, e000651.		29
41	Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis. British Journal of Cancer, 2015, 113, 1581-1589.	6.4	28
42	Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3â€“grabbing non-integrinâ€“positive macrophages associated with immune evasion in gastric cancer. European Journal of Cancer, 2020, 128, 27-37.	2.8	28
43	Immunosuppressive tumor-associated macrophages expressing interleukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. , 2022, 10, e003416.		28
44	Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma. BMC Cancer, 2015, 15, 67.	2.6	27
45	CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma. European Journal of Cancer, 2015, 51, 1953-1961.	2.8	24
46	Tumor-infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer. Cancer Science, 2018, 109, 2266-2274.	3.9	24
47	Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma. Oncotarget, 2016, 7, 32723-32730.	1.8	24
48	High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Cancer Science, 2015, 106, 592-597.	3.9	23
49	High Level of Anaphylatoxin C5a Predicts Poor Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma. Scientific Reports, 2016, 6, 29177.	3.3	23
50	Tumor-infiltrating TNFRSF9 ⁺ CD8 ⁺ T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response. Oncoimmunology, 2020, 9, 1838141.	4.6	23
51	Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget, 2016, 7, 13976-13983.	1.8	23
52	Association of O ⁶ -Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. JAMA Surgery, 2017, 152, e173120.	4.3	22
53	Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. International Journal of Cancer, 2020, 146, 542-552.	5.1	22
54	Tumor Suppressive Function of p21-activated Kinase 6 in Hepatocellular Carcinoma. Journal of Biological Chemistry, 2015, 290, 28489-28501.	3.4	20

#	ARTICLE	IF	CITATIONS
55	Interleukin-13 receptor $\hat{I}\pm 2$ is associated with poor prognosis in patients with gastric cancer after gastrectomy. <i>Oncotarget</i> , 2016, 7, 49281-49288.	1.8	20
56	Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1497-1506.	4.2	20
57	Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 50017-50026.	1.8	19
58	Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 80925-80934.	1.8	18
59	Prognostic significance of ST3GAL-1 expression in patients with clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2015, 15, 880.	2.6	17
60	Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma. <i>Tumor Biology</i> , 2016, 37, 4613-4620.	1.8	17
61	Evaluation of Tumor Pseudocapsule Status and its Prognostic Significance in Renal Cell Carcinoma. <i>Journal of Urology</i> , 2018, 199, 915-920.	0.4	17
62	Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. <i>Oncolmunology</i> , 2021, 10, 1915560.	4.6	17
63	Latency-associated Peptide Identifies Immunoevasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness. <i>Annals of Surgery</i> , 2022, 275, e163-e173.	4.2	17
64	Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 202-209.	1.3	16
65	C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. <i>Oncolmunology</i> , 2018, 7, e1433517.	4.6	16
66	Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1327-1336.	4.2	16
67	Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 6439-6450.	1.5	16
68	CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. <i>British Journal of Cancer</i> , 2022, 126, 1581-1588.	6.4	16
69	Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery. <i>Tumor Biology</i> , 2016, 37, 12635-12642.	1.8	15
70	B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients. <i>BMC Cancer</i> , 2018, 18, 590.	2.6	15
71	CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma. , 2020, 8, e000228.		15
72	<scp>Lymphocyteâ€activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epsteinâ€Barr virusâ€positive and MLH1â€defective gastric cancer patients</scp>. <i>International Journal of Cancer</i> , 2021, 148, 759-768.	5.1	15

#	ARTICLE	IF	CITATIONS
73	Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer. <i>European Journal of Cancer</i> , 2021, 157, 114-123.	2.8	15
74	Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 1594-603.	0.5	15
75	Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients. <i>BMC Cancer</i> , 2018, 18, 313.	2.6	14
76	Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 41.e11-41.e18.	1.6	14
77	Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. <i>Oncolmmunology</i> , 2021, 10, 1975386.	4.6	14
78	Snail predicts recurrence and survival of patients with localized clear cell renal cell carcinoma after surgical resection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 69.e1-69.e10.	1.6	13
79	IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma. <i>Tumor Biology</i> , 2016, 37, 11127-11134.	1.8	13
80	Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin ⁺ cell abundance. <i>Oncolmmunology</i> , 2020, 9, 1747333.	4.6	13
81	GALNT4 Predicts Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 1534-1541.	0.4	12
82	Prognostic significance of β 1,6-N-acetylglucosaminyltransferase V expression in patients with hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 844-853.	1.3	12
83	Dectin-1 predicts adverse postoperative prognosis of patients with clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2016, 6, 32657.	3.3	12
84	High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 238.e19-238.e26.	1.6	12
85	High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 7548-7558.	1.8	12
86	Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. <i>Oncolmmunology</i> , 2019, 8, e1515611.	4.6	12
87	Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 84775-84784.	1.8	12
88	TIM3+ cells in gastric cancer: clinical correlates and association with immune context. <i>British Journal of Cancer</i> , 2022, 126, 100-108.	6.4	12
89	Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer. , 2022, 10, e004047.		12
90	High mucin-7 expression is an independent predictor of adverse clinical outcomes in patients with clear-cell renal cell carcinoma. <i>Tumor Biology</i> , 2016, 37, 15193-15201.	1.8	11

#	ARTICLE	IF	CITATIONS
91	Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. <i>Tumor Biology</i> , 2016, 37, 4523-4529.	1.8	11
92	High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 1044-1052.	1.5	11
93	High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 35244-35254.	1.8	11
94	An Indel Polymorphism within pre-miR3131 Confers Risk for Hepatocellular Carcinoma. <i>Carcinogenesis</i> , 2017, 38, bgw206.	2.8	10
95	High expression of CXC chemokine receptor 6 associates with poor prognosis in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 675.e17-675.e24.	1.6	10
96	Prognostic value of copper transporter 1 expression in patients with clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2017, 14, 5791-5800.	1.8	10
97	Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. <i>BMC Cancer</i> , 2017, 17, 70.	2.6	10
98	PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 293-304.	1.6	10
99	CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients. <i>Oncotarget</i> , 2017, 8, 20328-20339.	1.8	10
100	Î²1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. <i>World Journal of Urology</i> , 2015, 33, 1791-1799.	2.2	9
101	Prognostic value of UTX expression in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 338.e19-338.e27.	1.6	9
102	Decreased expression of Siglec-8 associates with poor prognosis in patients with gastric cancer after surgical resection. <i>Tumor Biology</i> , 2016, 37, 10883-10891.	1.8	9
103	Functional Short Tandem Repeat Polymorphism of PTPN11 and Susceptibility to Hepatocellular Carcinoma in Chinese Populations. <i>PLoS ONE</i> , 2014, 9, e106841.	2.5	9
104	High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 59777-59790.	1.8	9
105	High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 61036-61047.	1.8	9
106	Prognostic value of granulocyte colony-stimulating factor in patients with non-metastatic clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 69961-69971.	1.8	9
107	High expression of C-C chemokine receptor 2 associates with poor overall survival in gastric cancer patients after surgical resection. <i>Oncotarget</i> , 2016, 7, 23909-23918.	1.8	9
108	p21-Activated kinase 4 predicts early recurrence and poor survival in patients with nonmetastatic clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 205.e13-205.e21.	1.6	8

#	ARTICLE	IF	CITATIONS
109	Increased expression of C-C motif ligand 2 associates with poor prognosis in patients with gastric cancer after gastrectomy. <i>Tumor Biology</i> , 2016, 37, 3285-3293.	1.8	8
110	Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer. <i>International Journal of Cancer</i> , 2020, 147, 3539-3549.	5.1	8
111	High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 63661-63668.	1.8	8
112	IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 44186-44194.	1.8	8
113	Positive intratumoral chemokine (C-C motif) receptor 8 expression predicts high recurrence risk of post-operation clear-cell renal cell carcinoma patients. <i>Oncotarget</i> , 2016, 7, 8413-8421.	1.8	8
114	Notch1 Predicts Recurrence and Survival of Patients With Clear-cell Renal Cell Carcinoma After Surgical Resection. <i>Urology</i> , 2015, 85, 483.e9-483.e14.	1.0	7
115	p21-activated kinase-1 predicts recurrence and survival in patients with non-metastatic clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2015, 22, 447-453.	1.0	7
116	Decreased expression of JMJD3 predicts poor prognosis of patients with clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2017, 14, 1550-1560.	1.8	7
117	HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 79-87.	4.2	7
118	Tumor-infiltrating podoplanin ⁺ cells in gastric cancer: clinical outcomes and association with immune contexture. <i>Oncolmmunology</i> , 2020, 9, 1845038.	4.6	7
119	High expression of galectin-7 associates with poor overall survival in patients with non-metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , 0, 7, 41986-41995.	1.8	7
120	TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. <i>British Journal of Cancer</i> , 2022, 126, 1310-1317.	6.4	7
121	The Presence of Vascular Mimicry Predicts High Risk of Clear Cell Renal Cell Carcinoma after Radical Nephrectomy. <i>Journal of Urology</i> , 2016, 196, 335-342.	0.4	6
122	Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 5.e1-5.e9.	1.6	6
123	Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 117.	2.6	6
124	High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients. <i>Oncolmmunology</i> , 2017, 6, e1359450.	4.6	6
125	Tumor-infiltrating IL-17A ⁺ cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer. <i>Oncolmmunology</i> , 2020, 9, 1747332.	4.6	6
126	A three-molecule score based on Notch pathway predicts poor prognosis in non-metastasis clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 68559-68570.	1.8	6

#	ARTICLE	IF	CITATIONS
127	Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 25650-25659.	1.8	6
128	Stathmin 1 expression predicts prognosis and benefits from adjuvant chemotherapy in patients with gallbladder carcinoma. <i>Oncotarget</i> , 2017, 8, 108548-108555.	1.8	6
129	Granulocyte macrophage colony-stimulating factor predicts postoperative recurrence of clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 24527-24536.	1.8	6
130	Decreased expression of mucin 18 is associated with unfavorable postoperative prognosis in patients with clear cell renal cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 11005-14.	0.5	6
131	Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e15-166.e25.	1.6	6
132	B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer. <i>European Journal of Cancer</i> , 2022, 171, 133-142.	2.8	6
133	Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 112.e1-112.e8.	1.6	5
134	Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831769141.	1.8	5
135	Prognostic value of vascular mimicry in patients with urothelial carcinoma of the bladder after radical cystectomy. <i>Oncotarget</i> , 2016, 7, 76214-76223.	1.8	5
136	NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. , 2022, 10, e004569.		5
137	High peritumoral Bmi-1 expression is an independent prognosticator of poor prognosis in renal cell carcinoma. <i>Tumor Biology</i> , 2015, 36, 8007-8014.	1.8	4
138	Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. <i>Scientific Reports</i> , 2016, 6, 38364.	3.3	4
139	Podoplanin associates with adverse postoperative prognosis of patients with clear cell renal cell carcinoma. <i>Cancer Science</i> , 2016, 107, 1243-1249.	3.9	4
140	Enhancement of Siglec-8 expression predicts adverse prognosis in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 607.e1-607.e8.	1.6	4
141	Prognostic and Predictive Value of O6-methylguanine Methyltransferase for Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 342-348.	1.5	4
142	Intratumoral CCR5 ⁺ neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses. <i>Oncolimmunology</i> , 2020, 9, 1802176.	4.6	4
143	Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma. <i>Oncotarget</i> , 2018, 9, 3112-3120.	1.8	4
144	Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 14995-15003.	1.8	4

#	ARTICLE	IF	CITATIONS
145	Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	4
146	Poor clinical outcomes and immunoevasive contexture in SIRP ⁺ tumor-associated macrophages enriched muscle-invasive bladder cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 109.e11-109.e20.	1.6	3
147	Expression of Jagged1 predicts postoperative clinical outcome of patients with gastric cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 14782-92.	1.3	3
148	Decreased expression of granulocyte-macrophage colony-stimulating factor is associated with adverse clinical outcome in patients with gastric cancer undergoing gastrectomy. <i>Oncology Letters</i> , 2017, 14, 4701-4707.	1.8	2
149	CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 242.e15-242.e21.	1.6	2
150	Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	4.2	2
151	Failure to Cite Related Studies and Report Complete Information on Patients and Tissue Samples. <i>JAMA Surgery</i> , 2019, 154, 362.	4.3	1
152	ASO Author Reflections: Optimization of Tumor Therapy for the Specific Immune Microenvironment of Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6451-6452.	1.5	1
153	Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2117-2126.	4.2	1
154	High truncated-O-glycan score predicts adverse clinical outcome in patients with localized clear-cell renal cell carcinoma after surgery. <i>Oncotarget</i> , 2017, 8, 80083-80092.	1.8	0
155	ASO Visual Abstract: Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 2504-2504.	1.5	0